Chikungunya Vaccine Market Research Report—Global Forecast till 2030

Chikungunya Vaccine Market: Information by Product Technology (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccine, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates and Others), by Age Group (Pediatric, Adult and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2030

ID: MRFR/HC/9547-CR | November 2022 | Region: Global | 141 Pages         

Chikungunya Vaccine Market

Chikungunya Vaccine Market is expected to grow USD 496.67 million at a CAGR 10.12% during the forecast period 2022-2030.

Segmentation
By Product Technology Live-Attenuated Virus Vaccines Inactivated Viral Vaccine Recombinant Viral Vaccines Chimeric-Alphavirus Candidates and Others
By Age Group Pediatric Adult and Geriatric
By Distrubition Channel Hospital Pharmacies Retail Pharmacies and Others
Key Players
Companies Profiled   Takeda Pharmaceutical Company Limited (Japan)    Valneva SE (France)    Moderna Inc (China)    Emergent BioSolutions Inc (US)    Bharat Biotech International Limited (India)    Thermis Bioscience GmbH (Austria) and Auro Vaccine LLC (US)
Drivers
Market Driving Forces   Rising prevalence of chikungunya fever    Increasing awareness about mosquito-transmitted infections    Increasing government initiatives regarding prevention and control of chikungunya
Request a Free Sample

Chikungunya Vaccine Market Overview


The Chikungunya Vaccine Market is expected to reach USD 496.67 million by 2030 and register a CAGR of 10.12% during the forecast period of 2022 to 2030. Chikungunya vaccines include vaccines such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, and others. Rising prevalence of chikungunya fever, increasing awareness about mosquito-transmitted infections, and increasing government initiatives regarding the prevention and control of chikungunya fueling the market growth of chikungunya vaccine in forecast period. However, stringent regulatory requirements hamper the growth of the chikungunya vaccines market. On the other hand, the rising unmet needs for chikungunya treatment in developing and underdeveloped countries are expected to create lucrative growth opportunities for players operating in the chikungunya vaccines market.


Impact of COVID-19


Patients struggled to obtain their usual chikungunya treatments during the covid-19 outbreak. Furthermore, measures taken by various countries against covid-19 impacted the supply chain of raw materials for chikungunya vaccine development. Many countries across all regions have reported an overall shortage of raw materials required for vaccine and drug development. At the end of 2022, Since, the restrictions on the supply chain were lifted, the governments of various countries are lifting the supply chain restrictions. Various market players have resumed vaccine development operations. Moreover, the global covid-19 pandemic has had a substantial effect on the conduct of scientific research and clinical trials worldwide. Clinical trials for chikungunya were terminated because of the challenges of clinical research during the pandemic. According to data published in the lancet journal, over 2,000 clinical trials registered on clinicaltrials.gov were terminated because of the challenges of clinical research during the pandemic. Numerous companies shifted their focus on the development of vaccines for covid-19 from vaccine development for other diseases. In the US, the food and drug administration issued guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the covid-19 public health emergency.


Market Dynamics


Drivers



  • Rising prevalence of chikungunya fever


Chikungunya is a viral disease caused by the Chikungunya virus (CHIKV) and transmitted to humans by infected mosquitoes. Most commonly, the mosquitoes involved in the transmission cycle of chikungunya are Aedes albopictus and Aedes aegypti. According to the data published by European Centre for Disease Prevention and Control, 229,029 cases and 41 deaths of chikungunya have been reported across the globe as of as of August 2022.


Increasing awareness about mosquito-transmitted infections



  • Increasing government initiatives regarding prevention and control of chikungunya


Restraints



  • Stringent regulatory requirements


The chikungunya vaccine is the most cost-effective preventive measure for chikungunya disease. Currently, there is no approved preventive vaccine available in the market. Regulatory considerations are needed in the development of vaccines. In the US, the Food and Drug Administration (FDA) regulates vaccine development. The U.S. Food and Drug Administration (FDA) must license (approve) a vaccine before it can be used in the US that ensures safety, purity, potency, and effectiveness of the vaccine. The Indian Council of Medical Research (ICMR) guidelines established the standards of conduct for Phase I through IV clinical trials as well as research on combination vaccines. The regulatory policies are different in various countries worldwide. This is a restraining factor for the players involved in the global chikungunya vaccine market.


Opportunity


Rising unmet needs for chikungunya treatment in developing and underdeveloped countries


According to the WHO, chikungunya disease mostly occurs in Africa, Asia, and the Indian subcontinent. Also, according to the National Center of Biotechnology Information, there have been a growing number of reports of chikungunya virus infections in African countries, in Southeast Asia, and on the Indian subcontinent in the last 20 years. Moreover, the number of people suffering from disease is increasing in Latin American countries. For instance, 162,407 probable cases of chikungunya were recorded in Brazil until August 31, according to the Brazil Ministry of Health, a rise of 89.4% over the same time in 2021.


Supply Chain Analysis


The global chikungunya vaccine market is growing steadily and is expected to grow significantly over the forecast period. This is due to the increasing contribution of existing players to make their services more efficient. The value chain analysis for the market of chikungunya vaccine comprises four major components: R&D and designing, manufacturing, distribution, marketing & sales, and post-sales monitoring.


The R&D process aims to design and develop the physical, chemical, and biological effects of vaccines on humans under different conditions. R&D is a costly and long-term process; hence, innovative activities are carried out in partnerships with global, regional, or local players. In manufacturing process, product strategies are ready. The manufacturing process starts with the assembling of components. Manufacturing is a fast process, followed by testing the quality of the products. Companies that manufacture chikungunya vaccine products may either manufacture their products in-house or outsource their work to contract research organizations (CRO's) and contract manufacturing organizations (CMOs). This process can be optimized by understanding the factors affecting production efficiency. This process requires following stringent compliance requirements from different health authorities. Distribution and sales are the most crucial parts of the market. In the chikungunya vaccine market, distribution and sales channels consist of intermediaries, direct selling, online channels, retailers, and others. Chikungunya vaccines are prescription products delivered to hospitals, clinics, and pharmaceutical stores where the seller asks for a prescription before the sale and delivery of the product. and lastly, post-sales monitoring plays a very important role in this market. As the global market is competitive and patient-centric, post-sales monitoring is a must to understand product performance.


Segment Overview:


The global market of chikungunya vaccine is segmented into technology, age group and distribution channel.


By Product Type


Global Chikungunya Vaccine Market Share (%), by Technology, 2021Chikungunya Vaccine Market Share (%), by Technology, 2021Source: MRFR Analysis



  • Live-Attenuated Virus Vaccines

  • Inactivated Viral Vaccine

  • Recombinant Viral Vaccines

  • Chimeric-Alphavirus Candidates

  • Others


By Age Group



  • Pediatric

  • Adult

  • Geriatric


By Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Others


Regional Analysis


The global chikungunya vaccine market has been segmented, on the basis of region, into North America, Europe, Asia-Pacific, and the Rest of the World.


Global Chikungunya Vaccine Market Share (%), by Region, 2021Chikungunya Vaccine Market Share (%), by Region, 2021Source: MRFR Analysis



  • North America

  • Europe

  • Asia-Pacific

  • Rest of the World


Competitive Landscape


The global chikungunya vaccine market is expected to grow significantly in the coming years due to the rising prevalence of chikungunya fever and increasing healthcare expenditure. The global market of chikungunya vaccine is characterized by the presence of several global and regional vendors. The market is highly competitive, with all the players trying to gain maximum market share. The vendors compete based on cost, quality, and reliability. It is crucial for the players to offer cost-efficient and advanced vaccines to succeed in an intensely competitive market environment. Because of increased adoption of advanced medical technologies and continuous development by companies, the global market of chikungunya vaccine is becoming more profitable. The market is moderately fragmented due to rising competition, product launches, increased collaborative partnerships, and other strategic decisions to achieve operational efficiency.


For instance, Takeda Pharmaceutical Company Limited (Takeda) is a patient-focused, values-based, R&D-driven global biopharmaceutical company. It is one of the largest pharmaceutical companies in Asia. The company's therapeutic focus is oncology, gastroenterology, the central nervous system, rare diseases, and vaccines. It delivers highly innovative medicines and transformative care for more people globally. It has a presence in approximately 80 countries, with leading positions in Japan and the US. Chikungunya Vaccine (TAK-507) is a vaccine product.


Key Players


The prominent players in the global chikungunya vaccine market are Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna, Inc. (China) are the other major players dominating the market of chikungunya vaccine. Other key players contributing to the market growth include Emergent BioSolutions Inc. (US), Bharat Biotech International Limited (India), Thermis Bioscience GmbH (Austria) and Auro Vaccine LLC. (US).


Report Overview


The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, value chain, and impact of COVID-19 on the market.


Market Segmentation


Global Chikungunya Vaccine Market, by Technology



Global Chikungunya Vaccine Market, by Age Group



  • Pediatric

  • Adult

  • Geriatric


Global Chikungunya Vaccine Market, by Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Others


Global Chikungunya Vaccine Market, by Region




  • North America

    • US

    • Canada




  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Rest of the World

    • Middle East

    • Africa

    • Latin America




Intended Audience



  • Hospitals

  • Clinics

  • Research Institutes

  • Vaccine Manufacturers

  • Healthcare IT Companies



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 496.67 Million
  CAGR   10.12%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2018 to 2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Technology, Age Group, Distribution Channel, and Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna, Inc. (China), Emergent BioSolutions Inc. (US), Bharat Biotech International Limited (India), Thermis Bioscience GmbH (Austria) and Auro Vaccine LLC. (US)
  Key Market Opportunities   â€¢ Rising unmet needs for chikungunya treatment in developing and underdeveloped countries
  Key Market Drivers   â€¢ Rising prevalence of chikungunya fever • Increasing awareness about mosquito-transmitted infections • Increasing government initiatives regarding prevention and control of chikungunya


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The Chikungunya Vaccine Market is anticipated to reach USD 496.67 million at CAGR of 10.12% during the forecast period of 2022 to 2030.

Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna, Inc. (China), Emergent BioSolutions Inc. (US), Bharat Biotech International Limited (India), Thermis Bioscience GmbH (Austria) and Auro Vaccine LLC. (US) are the key competitors in the market of Chikungunya Vaccine

North America holds the largest share in the global market of Chikungunya Vaccine

Rising prevalence of chikungunya fever and Increasing awareness about mosquito-transmitted infections are the key factors driving the market of Chikungunya Vaccine

Stringent regulatory requirements may limit the market growth of Chikungunya Vaccine